Targeting specific genomic mutation in breast cancer improves outcomes, first study shows
Targeting a common mutation in patients with hormone receptor positive (HR+) HER2 negative (HER2-) advanced breast cancer with the alpha-specific phosphatidylinositol-3-kinase (PI3K) inhibitor alpelisib significantly improves ...
Oct 22, 2018
0
0